Fortune January 21, 2025
Have you been mulling over the idea of taking weight-loss medication but unable to take the plunge, so to speak, with injectables? Help may soon be on the way.
Eli Lilly & Co., the Fortune 500 pharma firm that manufactures weight-loss injection Zepbound (tirzepatide), has a comparable oral medication in the works that could be approved by the Food and Drug Administration as early as next year, according to CEO Dave Ricks.
“It’s highly anticipated and really important,” he told Bloomberg TV on Jan. 13 at the annual JPMorgan Healthcare Conference in San Francisco. “The benefit here is not just the convenience of the pill...
Today's Sponsors
Today's Sponsor